Glaxo to begin clinical trial of Ebola vaccine

GlaxoSmithKline (NYSE:GSK) is set to begin a clinical trial of an experimental vaccine against Ebola, which is being co-developed with U.S. scientists.

The experimental vaccine has already produced promising results in animal studies, and with an approval from the FDA, it will enter initial Phase I testing in humans.

Still, the new vaccine will not be ready for widespread deployment before 2015 - even assuming it works as well as hoped.

From other sites
Comments (1)
  • Urbannek
    , contributor
    Comments (1507) | Send Message
    Great! Hope it works.
    11 Aug 2014, 04:50 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs